DEPO - Depomed, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
8.17
-0.04 (-0.49%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close8.21
Open8.21
Bid6.15 x 4000
Ask8.83 x 1000
Day's Range8.09 - 8.29
52 Week Range4.31 - 10.97
Volume476,288
Avg. Volume1,458,474
Market Cap519.509M
Beta0.93
PE Ratio (TTM)N/A
EPS (TTM)-0.67
Earnings DateAug 8, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.17
Trade prices are not sourced from all markets
  • ACCESSWIRE10 days ago

    Today's Research Reports on Trending Tickers: OPKO Health and Depomed

    NEW YORK, NY / ACCESSWIRE / July 10, 2018 / U.S. equities continued to push higher on Monday, as strong economic data counters worries on rising trade tensions. The Dow Jones Industrial Average advanced ...

  • The Wall Street Journal10 days ago

    [$$] Depomed, Purdue Pharma Move to Resolve Patent Dispute

    Inc. and Purdue Pharma LP are trying to resolve a patent dispute involving Purdue’s painkiller OxyContin. The companies didn’t disclose terms of the settlement talks Monday, but Janney Montgomery Scott’s Ken Trbovich said a settlement could “easily support the lower end” of his April 2016 forecast of potential royalties for Depomed of $3 to $8 a share on an estimated $10 billion in cumulative OxyContin sales. By Mr. Trbovich’s estimate, Depomed could bring in about $190 million, or about one-third of its market value as of Monday’s closing, which reflected a 19% surge on news of the settlement discussions.

  • GlobeNewswire11 days ago

    Depomed to Report Second-Quarter 2018 Financial Results on Wednesday, August 8, 2018

    LAKE FOREST, Ill., July 09, 2018-- Depomed, Inc. today announced that it will release second-quarter 2018 financial results on Wednesday, August 8, 2018, before the open of markets. Following the announcement, ...

  • ACCESSWIRE11 days ago

    Complimentary Technical Snapshots on Teva Pharma Industries and Three More Drug Makers Stocks

    Stock Research Monitor: DEPO, DRRX, and ENDP LONDON, UK / ACCESSWIRE / July 9, 2018 / If you want a free Stock Review on TEVA sign up now at www.wallstequities.com/registration . In today's pre-market ...

  • GlobeNewswire14 days ago

    Depomed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Depomed, Inc. (DEPO) announced that effective July 3, 2018, the Company granted ten newly-hired employees a total of 512,439 restricted stock units (“RSUs”).  The RSUs were granted as inducements material to each such individual’s entry into employment with Depomed in accordance with NASDAQ Listing Rule 5635(c)(4).  The RSUs are subject to such employee’s continued service relationship with the Company, the terms and conditions of the Company's 2014 Omnibus Incentive Plan and the award agreements pursuant to which they were granted. Depomed is a leading specialty pharmaceutical company committed to putting the patient first in everything it does. Depomed is focused on enhancing the lives of patients, families, physicians, providers and payors through the commercialization of products in the areas of pain and neurology, and in the development of drugs in areas of unmet medical need.

  • GlobeNewswirelast month

    Depomed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Depomed, Inc. (DEPO) announced that the Company will grant Phillip B. Donenberg, the Company’s new Chief Financial Officer and Senior Vice President, 87,163 restricted stock units (“RSUs”) and 87,163 target performance stock units (“PSUs”), in each case effective upon the commencement of his employment with the Company on July 16, 2018. The RSUs and PSUs will be granted as inducements material to Mr. Donenberg’s entry into employment with Depomed in accordance with NASDAQ Listing Rule 5635(c)(4). The RSUs and PSUs will be subject to Mr. Donenberg’s continued service relationship with the Company, and to the terms and conditions of the Company's 2014 Omnibus Incentive Plan and the award agreements pursuant to which they were granted.

  • ACCESSWIRElast month

    Free Daily Technical Summary Reports on Endo International and Three Other Healthcare Stocks

    Stock Research Monitor: ZGNX, DEPO, and DRRX LONDON, UK / ACCESSWIRE / June 7, 2018 / If you want a free Stock Review on ENDP sign up now at www.wallstequities.com/registration . Ahead of today's trading ...

  • GlobeNewswirelast month

    Depomed Announces the Appointment of Phillip B. Donenberg as Chief Financial Officer

    Lake Forest, Illinois, June 5, 2018 - Depomed, Inc. (DEPO) today announced that it has appointed Phillip B. Donenberg as Chief Financial Officer and Senior Vice President, effective July 16, 2018. Mr. Donenberg will succeed August J. Moretti who has served as Depomed’s Chief Financial Officer since January 2012. "Phil brings exceptional finance experience and a proven track record of success, most recently as CFO of AveXis," said Arthur Higgins, President and Chief Executive Officer of Depomed.

  • Why Depomed Inc.'s Shares Soared 23.2% Higher
    Motley Fool2 months ago

    Why Depomed Inc.'s Shares Soared 23.2% Higher

    The company rewarded investors with good news today.

  • GlobeNewswire2 months ago

    Depomed Announces First-Quarter 2018 Financial Results

    -Company Confirms Previous 2018 Guidance for Neurology Franchise Net Sales and Non-GAAP Adjusted EBITDA-. -Amends Existing Agreement for CAMBIA Line Extension–. -Announces New Co-Promotion Agreement for ...

  • GlobeNewswire2 months ago

    Depomed to Present at the UBS Global Healthcare Conference

    LAKE FOREST, Ill., May 07, 2018-- Depomed, Inc. today announced that members of senior management will participate at the 2018 UBS Global Healthcare Conference in a session scheduled for 1:30 pm ET on ...

  • GlobeNewswire3 months ago

    Depomed to Report First-Quarter 2018 Financial Results on Thursday, May 10, 2018

    Depomed, Inc. (DEPO) today announced that it will release first-quarter 2018 financial results on Thursday, May 10, 2018, before the open of markets. Following the announcement, the Company will host a conference call beginning at 8:30 a.m. ET to discuss its results. Participants can access the live webcast from the Investor Relations section of Depomed's website at http://www.depomed.com.

  • Drug stocks dive as Trump says he's considering suing drugmakers over opioid crisis
    CNBC4 months ago

    Drug stocks dive as Trump says he's considering suing drugmakers over opioid crisis

    President Donald Trump said he's considering suing drugmakers for their role in fueling the opioid epidemic, sending pharma stocks tumbling.

  • CNBC4 months ago

    Drug stocks dive as Trump says he's considering suing drugmakers over opioid crisis

    President Donald Trump said he's considering suing drugmakers for their role in fueling the opioid epidemic, sending pharma stocks tumbling.

  • This Biotech Flirts With Breakout Amid Battle With Opioid Makers
    Investor's Business Daily4 months ago

    This Biotech Flirts With Breakout Amid Battle With Opioid Makers

    Collegium touched a buy zone Thursday after sales of painkiller Xtampza easily beat Street expectations in the fourth quarter.

  • Exploring Depomed’s Financial Performance Today
    Market Realist4 months ago

    Exploring Depomed’s Financial Performance Today

    In fiscal 2017, Depomed (DEPO) generated total revenues of $380.7 million. Of these total revenues, $379.8 million came from product sales, and ~$844,000 came from royalties. By comparison, the company had generated total revenues of $455.8 million in fiscal 2016, of which $455 million came from product sales and $831 million from royalties.

  • Depomed versus Peers in March 2018: Analyst Ratings
    Market Realist4 months ago

    Depomed versus Peers in March 2018: Analyst Ratings

    Depomed (DEPO) is a specialty pharmaceutical company with a focus on pain and CNS (central nervous system) conditions. In March 2018, two of the seven analysts covering Depomed have given the stock a “buy” rating. By comparison, of the 22 analysts covering Merck (MRK) in March 2018, six analysts have given the stock a “strong buy” rating, and seven analysts have given it a “buy” rating, while nine analysts have given it a “hold” rating.

  • Inside Depomed’s Portfolio: The Key Drugs
    Market Realist4 months ago

    Inside Depomed’s Portfolio: The Key Drugs

    Depomed (DEPO) generates a major part of its sales from five major products: Nucynta, Gralise, Cambia, Lazanda, and Zipsor. Sales of products in Depomed’s Nucynta franchise fell from $281.2 million in fiscal 2016 to $239.5 million in fiscal 2017. Depomed acquired the Nucynta franchise from Janssen in April 2015.

  • Behind Depomed’s Business Strategy
    Market Realist4 months ago

    Behind Depomed’s Business Strategy

    Depomed (DEPO) has adopted a three-pronged business strategy with three key elements: maintain, build, and grow. Depomed aims to maintain its Nucynta franchise of pain products through the commercialization agreement it entered into with Collegium Pharmaceutical in December 2017. Under this agreement, Depomed granted commercialization rights for the Nucynta franchise of pain products to Collegium Pharmaceutical in the US.